Baihealpharma

Baihe Alpha is a biotechnology company specializing in the discovery and development of innovative small molecule drugs targeting G protein-coupled receptors (GPCRs). The company utilizes a proprietary structure-based drug design (SBDD) platform integrated with high-resolution Cryo-Electron Microscopy (Cryo-EM) to overcome traditional challenges in GPCR drug discovery. Its lead candidate, BHA-001, is an oral small molecule GLP-1 receptor agonist currently in clinical development for the treatment of type 2 diabetes and obesity. Headquartered in Suzhou's BioBAY, Baihe Alpha focuses on high-value targets in metabolic diseases, endocrinology, and inflammatory conditions. The company's approach leverages deep structural insights to design potent, selective, and orally bioavailable therapeutics.